Akari Therapeutics Plc Annual Report - How They Did This Year

I’ve put together this guide to help you understand how Akari Therapeutics performed this year. Instead of digging through dense legal filings, I’ve broken down the key points so you can see the company’s health and direction clearly.

1. What does this company do?

Akari Therapeutics is a biotech company developing treatments for inflammatory and autoimmune diseases. This year, they made a major strategic shift by acquiring Peak Bio, Inc. in early 2024. This added PHP-303—an oral drug for inflammation—to their pipeline alongside their lead drug, nomacopan. The company is now moving from rare diseases to broader inflammatory conditions, betting its future on these two research programs.

2. Financial performance

Akari is in a "heavy investment" phase, which is common for biotech firms that aren't selling products yet. For the year ending December 31, 2024, the company had almost no revenue because none of their drugs are on the market. They spent about $15.2 million on research and $9.8 million on administrative costs. With a total loss of roughly $25 million, they rely entirely on outside funding. They ended the year with $4.2 million in cash, meaning they must raise money to fund ongoing operations.

3. Major wins and challenges

• The Big Win: Acquiring Peak Bio gave the company a more diverse portfolio. The Phase 2-ready PHP-303 helps balance the risks associated with their older nomacopan programs.
• The Hurdle: Integrating Peak Bio while maintaining cash reserves has been a primary focus. Management has actively managed this by raising money through multiple rounds of selling shares and restructuring debt to maintain operations.

4. Financial health: The "Dilution" Warning

You need to be very careful here. Akari is not profitable and depends on outside cash to survive. Throughout 2024 and early 2025, they frequently raised money, which often meant issuing more shares and reducing your ownership percentage.

• Share Offerings: They raised $12 million through several offerings. These often included warrants, which could increase the number of shares in existence.
• Warrant Overload: The company issued many types of warrants. If the stock price falls, the price to exercise these warrants often drops, allowing holders to buy more shares at lower prices. This further dilutes your stake.
• Equity Line of Credit: They have an agreement to sell up to $20 million in stock to White Lion Capital. This allows the company to sell shares whenever they need cash, which lowers the value of your existing holdings.

5. Key risks

The biggest risk is dilution. Because the company has no cash flow, they must issue new shares to fund research, shrinking your slice of the pie. They also face "binary risk": if their clinical trials fail, the company’s value could be significantly impacted because they have no products on the market to fall back on.

6. Future outlook

The company is focused on moving its new assets through clinical trials, with data for PHP-303 expected in the next 18 months. Their survival depends on raising more cash while hoping these drugs prove effective enough to attract a partner or buyer. Expect continued volatility and potential share sales as they work toward these clinical milestones.

---

Note: This report is based on provided financial data. Given the complex share structure and the company's reliance on external financing, this remains a very high-risk, speculative investment. Always consider your risk tolerance before investing in early-stage biotech.